Sign In

Time to take prevention to heart

Been for an MOT recent­ly? That’s a health MOT for you, not a road test for your car. By law we are com­pelled to sub­mit our motor vehi­cle, after a cer­tain age, for inspec­tion every year. Yet most of us spend far less time and mon­ey tak­ing stock of our own “road­wor­thi­ness”.

This could be about to change, with NHS Eng­land launch­ing a dri­ve to encour­age more over-40s to have a check-up to reduce the risk of heart attack and stroke. The ini­tia­tive brings togeth­er the NHS and Pub­lic Health Eng­land, promis­ing a more joined-up approach to car­dio­vas­cu­lar care. They say this will pre­vent almost 10,000 heart attacks and 29,000 strokes over the next three years, sav­ing the NHS more than £500 mil­lion.

The scheme, called the NHS Right-Care Car­dio­vas­cu­lar Dis­ease Pre­ven­tion Path­way, aims to iden­ti­fy peo­ple with heart dis­ease risk fac­tors by doing sim­ple checks at GP surg­eries and phar­ma­cies. It will also take steps to ensure that peo­ple who have pre­vi­ous­ly been diag­nosed with high blood pres­sure or high cho­les­terol are on the appro­pri­ate med­ica­tion.

So far the scheme has been rolled out at 84 of the 209 clin­i­cal com­mis­sion­ing groups (CCGs) in Eng­land, with plans to intro­duce it at the remain­ing CCGs with­in the next two years.

Sig­nif­i­cant resources are now being com­mit­ted to keep­ing peo­ple out of hos­pi­tal for as long as pos­si­ble

The pro­gramme is the lat­est exam­ple of how the focus of the health ser­vice is shift­ing from treat­ment to pre­ven­tion. While acknowl­edg­ing the impor­tance on invest­ing in effec­tive care path­ways, sig­nif­i­cant resources are now being com­mit­ted to keep­ing peo­ple out of hos­pi­tal for as long as pos­si­ble, for the mul­ti-bil­lion-pound cost of treat­ing so-called lifestyle dis­eases, such as car­dio­vas­cu­lar dis­ease (CVD) and dia­betes, is threat­en­ing to over­whelm hos­pi­tal trusts.

As Simon Stephens, NHS chief exec­u­tive, says in the NHS Five-Year For­ward View, it makes lit­tle sense that the health ser­vice is now spend­ing more on bariatric surgery for obe­si­ty than on a nation­al roll-out of inten­sive lifestyle inter­ven­tion pro­grammes that were first shown to cut obe­si­ty and pre­vent dia­betes over a decade ago.

Action is being tak­en on a num­ber of oth­er fronts, from high­er tax­es on sug­ary drinks to repur­pos­ing smok­ing ces­sa­tion schemes. There are high hopes for the sug­ar tax, which takes effect from April 2018.  The tax will be imposed on com­pa­nies accord­ing to the vol­ume of the sug­ar-sweet­ened drinks they pro­duce or import.

There will be two bands; one is for total sug­ar con­tent above 5g per 100 mil­li­l­itres and a sec­ond, high­er band for the most sug­ary drinks with more than 8g per 100 mil­li­l­itres. Analy­sis by the Office for Bud­getary Respon­si­bil­i­ty sug­gests they will be levied at 18p and 24p per litre.

Exam­ples of drinks which would cur­rent­ly fall under the high­er rate of the sug­ar tax include full-strength Coca-Cola and Pep­si, Lucozade Ener­gy and Irn-Bru. The low­er rate would catch drinks such as Dr Pep­per, Fan­ta, Sprite, Schweppes Indi­an ton­ic water and alco­hol-free shandy.

Cam­paign­ers hope high­er prices will encour­age con­sumers to mod­er­ate con­sump­tion. Man­u­fac­tur­ers have reduced sug­ar con­tent in some drinks in advance of the new tax, so it appears to already be hav­ing a pos­i­tive effect.

Cardiovascular health smoking risk

The gov­ern­ment aims to cut the adult smok­ing rate to 12 per cent from 15.5 per cent at present with­in five years

The gov­ern­ment has relaunched its anti-smok­ing strat­e­gy, with a tar­get to cut the adult smok­ing rate to 12 per cent from 15.5 per cent at present with­in five years. The tobac­co con­trol plan will tar­get chil­dren and preg­nant women, in par­tic­u­lar, and have a focus on the poor­est com­mu­ni­ties where smok­ing rates are high­est.

Less high-pro­file ini­tia­tives are also under­way. For exam­ple, nation­al pro­cure­ment stan­dards have been intro­duced for cater­ers, with strict nutri­tion­al cri­te­ria, aimed at cre­at­ing a health­i­er envi­ron­ment in the work­place.

But how far can the state involve itself in the lives of indi­vid­u­als before it is accused of being too intru­sive? A scheme to send those at high­est risk of devel­op­ing dia­betes to cook­ery class­es has met fierce oppo­si­tion, par­tic­u­lar­ly over the cost. Yet NICE, the health and care watch­dog, cal­cu­lates that the £435-a-head cours­es will pay for them­selves over 14 years by reduc­ing the NHS’s bill for treat­ing dia­betes, which cur­rent­ly stands at around £9 bil­lion a year.

As health author­i­ties tip­toe around pub­lic sen­si­tiv­i­ties over the degree of nan­ny­ing they are pre­pared to tol­er­ate, a sep­a­rate strat­e­gy to reduce CVD involves clin­i­cal inter­ven­tions. Up to six mil­lion adults in the UK cur­rent­ly take statins to low­er their cho­les­terol lev­els and there­by reduce the risk of heart attacks and strokes. Despite some con­cerns over side effects, there is a grow­ing body of evi­dence that sug­gests statins should be pre­scribed to almost twice as many peo­ple, many of whom are in rel­a­tive good health, but have high cho­les­terol.

Increas­ing­ly, this form of ear­ly inter­ven­tion is seen as an effec­tive way to pre­vent CVD and is the focus of sig­nif­i­cant invest­ment by the phar­ma­ceu­ti­cal indus­try. For exam­ple, there is strong inter­est in the new drug inclisir­an, which can dra­mat­i­cal­ly low­er blood cho­les­terol. The drug is giv­en twice a year with an injec­tion by a health pro­fes­sion­al, which has the added ben­e­fit of mak­ing it more like­ly that patients will adhere to the treat­ment.

Com­pli­ance is a recur­ring issue. A recent study pub­lished in BMJ Open esti­mat­ed that if 10 per cent of the 450,000 adults in the UK at risk of recur­rent CVD took a polyp­ill com­bin­ing aspirin, ator­vas­tatin and ramipril it would improve adher­ence to med­ica­tions and pre­vent an extra 3,000 heart attacks or strokes and 600 CVD deaths over a decade, com­pared with requir­ing patients to take three drugs sep­a­rate­ly. It appears that just as it is dif­fi­cult to per­suade peo­ple to live health­i­er lives, it is also a chal­lenge to per­suade them to take med­ica­tion pro­vid­ed to extend their lives.

Giv­en the scale of the prob­lem, gov­ern­ments will con­tin­ue to nudge, cajole, bribe and order peo­ple to do more to look after them­selves. But, in the end, this prob­lem has a sim­ple solu­tion – you are what you eat.